MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...
Foghorn Therapeutics (NASDAQ: FHTX) has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. Mr. Maynard brings more than 25 years of executive experience driving financial...
Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted AP-SA02 Qualified Infectious Disease Product (QIDP) designation for intravenous use in the adjunct treatment of complicated bacteremia...
Zura Bio (NASDAQ: ZURA) has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the...
C4 Therapeutics (NASDAQ: CCCC) has announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple...
Acrivon Therapeutics (NASDAQ: ACRV) has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in...
Lipocine (NASDAQ: LPCN) has announced that the last patient has completed the final study visit in the Phase 3 trial of its oral brexanolon, LPCN 1154, for the treatment of postpartum depression (PPD). According to...
Klotho Neurosciences (NASDAQ: KLTO) has announced that IP Australia has accepted 18 claims within its patent application covering the composition and use of its human secreted Klotho protein, s-KL isoform. The patent...
Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing...
Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with...